- Home
- OXSQ vs IPHA Comparison
OXSQ vs IPHA Comparison
Compare OXSQ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXSQ | IPHA |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OXSQ | IPHA |
|---|---|---|
| Price | $1.89 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.2M | 21.6K |
| Earning Date | 02-27-2026 | 09-17-2025 |
| Dividend Yield | ★ 22.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | $2.27 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $1.63 |
| 52 Week High | $2.87 | $2.63 |
Technical Indicators
Market Signals| Indicator | OXSQ | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 51.09 |
| Support Level | $1.82 | $1.74 |
| Resistance Level | $1.98 | $1.85 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 58.14 | 62.50 |
Price Performance
Historical ComparisonAbout OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.